Clarivate Epidemiology’s coverage of HD comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of HD for each country, as well as…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Huntington’s disease (HD) patient populations covering 171…
Clarivate Epidemiology’s coverage of primary sclerosing cholangitis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of malignant pleural mesothelioma (MPM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of mesothelioma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
MARKET OUTLOOKPolycythemia vera (PV) is a rare hematological malignancy estimated to affect 50,000 people in the United States. Patients can be classified as having low- or high-risk PV, each of…
Clarivate Epidemiology’s coverage of postherpetic neuralgia (PHN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pulmonary hypertension disease patient populations, covering 171…
Clarivate Epidemiology’s coverage of acute prophylaxis for venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets…